A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

This trial tests BL-M09D1, a new targeted drug (an antibody-drug conjugate) that delivers a cancer-killing agent directly to tumor cells, in people with advanced non-small cell lung cancer or other solid tumors that have stopped responding to standard treatments. The study aims to find the right dose and assess safety and effectiveness. **You may be eligible if...** - You are 18 or older with advanced non-small cell lung cancer or another solid tumor - Your cancer has progressed despite standard treatments - You have at least one measurable tumor on imaging - Your general health is good (ECOG 0–1) and your heart, liver, and kidney function meet requirements - You are willing to provide archived or fresh tumor tissue **You may NOT be eligible if...** - Your cancer has progressed too far or your health is too poor to tolerate treatment - You have significant heart problems (ejection fraction below 50%) - You are pregnant or breastfeeding - You have had recent serious side effects from prior cancer treatments that haven't resolved Talk to your doctor to see if this trial is right for you.